The oropharynx consists of the structures in the oral cavity, back of the throat, including the base of the tongue, palatine tonsils, posterior pharyngeal wall, and soft palate. These are the well-known areas can only be visualized using special endoscopes or mirrors. There are many types of cancer of the oropharynx.
Oropharyngeal cancer is a type of head and neck cancer. Patients with oropharyngeal cancer related to HPV tend to present earlier in life as compared to those with tobacco-associated oropharyngeal cancer. The primary tumor is often difficult to see, hidden within the folds of the throat (tongue-base and tonsil.)
DelveInsight’s “Oropharyngeal Cancer – Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Oropharyngeal Cancer, historical and forecasted epidemiology as well as the Oropharyngeal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Oropharyngeal Cancer market report provides current treatment practices, emerging drugs, Oropharyngeal Cancer market share of the individual therapies, current and forecasted Oropharyngeal Cancer market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Oropharyngeal Cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
View full report: https://www.delveinsight.com/report-store/oropharyngeal-cancer-market
Oropharyngeal Cancer Disease Understanding and Treatment Algorithm
Cancer specific to the oropharynx is called oropharyngeal cancer-a type of head and neck cancer that accounts for around thousands of newly diagnosed cases in the US every year. The leading cause of head and neck cancers is smoking tobacco, and as smoking has become less common in recent years, so has the occurrence for most head and neck cancers. The exception to this is oropharyngeal cancer, which is drastically increasing, especially in the younger population. The earliest stage oral cavity or oropharyngeal cancers are called stage 0 (carcinoma in situ), and then range from stages I through IV. As a rule, the lower the number, the less the cancer has spread. A higher number, such as stage IV, means cancer has spread more.
The DelveInsight Oropharyngeal Cancer market report gives a thorough understanding of the Oropharyngeal Cancer by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Oropharyngeal Cancer Epidemiology
Key Findings
1. As per the Surveillance, Epidemiology, and End Results (SEER), approximately 1.2% of men and women will be diagnosed with oral cavity and pharynx cancer at some point during their lifetime (based on 2015–2017 data).
2. According to the Stanford Medicine (US), Oropharyngeal Cancer cases typically are not diagnosed until the tumor metastasizes to the neck.
3. As per the CDC (Centers for Disease Control and Prevention), approximately 70% of cancers of the oropharynx may be linked to HPV.
Request for sample pages: https://www.delveinsight.com/sample-request/oropharyngeal-cancer-market
Oropharyngeal Cancer Drug Chapters
The dynamics of the Oropharyngeal Cancer market is anticipated to change in the coming years owing to the rise in numbers of company’s taking interest in development of drugs for Oropharyngeal Cancer. Key players, such as Precigen, and others are involved in developing drugs for Oropharyngeal Cancer.
Emerging therapies includes Validive by Monopar Therapeutics, ISA101b plus Cemiplimab by ISA Pharmaceuticals/ Regeneron Pharmaceuticals
Drug chapter segment of the Oropharyngeal Cancer report encloses the detailed analysis of Oropharyngeal Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Oropharyngeal Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Oropharyngeal Cancer Market Outlook
At present, there are several treatment choices for oropharyngeal cancer: surgery, radiation therapy, chemotherapy and targeted therapy. Treatment of oral cavity cancer is generally surgery followed by radiotherapy, whereas oropharyngeal cancers, which are more likely to be advanced at the time of diagnosis, are managed with radiotherapy or chemo-radiation. Even after the surgery, cancer cell can be seen, therefore, few patients may be given chemotherapy or radiation therapy to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.
The use of surgery in HPV-positive oropharyngeal cancer and the application of minimally invasive techniques to avoid or reduce required doses of adjuvant treatment have become important areas of study. Trans-oral laser surgery (TLS) was first popularized by Steiner in Germany. There has been increasing experience with TLS, but its use for oropharyngeal tumors has been limited to a few high-volume centers in the US and European units in the UK, France, and Germany
According to DelveInsight, Oropharyngeal Cancer market in 7MM is expected to change in the study period 2017-2030.
Scope of the Report
- The report covers the descriptive overview of Oropharyngeal Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Oropharyngeal Cancer epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Oropharyngeal Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Oropharyngeal Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Oropharyngeal Cancer market
Table of contents:
1. Key Insights
2. Executive Summary of Oropharyngeal Cancer
3. Competitive Intelligence Analysis for Oropharyngeal Cancer
4. Oropharyngeal Cancer: Market Overview at a Glance
4.1. Oropharyngeal Cancer Total Market Share (%) Distribution in 2017
4.2. Oropharyngeal Cancer Total Market Share (%) Distribution in 2030
5. Oropharyngeal Cancer: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Oropharyngeal Cancer Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Oropharyngeal Cancer Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Oropharyngeal Cancer Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Oropharyngeal Cancer Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Oropharyngeal Cancer Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Oropharyngeal Cancer Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Oropharyngeal Cancer Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Oropharyngeal Cancer Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Oropharyngeal Cancer Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Oropharyngeal Cancer Treatment and Management
8.2. Oropharyngeal Cancer Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Oropharyngeal Cancer Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Oropharyngeal Cancer: Seven Major Market Analysis
13.1. Key Findings
13.2. Oropharyngeal Cancer Market Size in 7MM
13.3. Oropharyngeal Cancer Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Oropharyngeal Cancer Total Market Size in the United States
15.1.2. Oropharyngeal Cancer Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Oropharyngeal Cancer Total Market Size in Germany
15.3.2. Oropharyngeal Cancer Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Oropharyngeal Cancer Total Market Size in France
15.4.2. Oropharyngeal Cancer Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Oropharyngeal Cancer Total Market Size in Italy
15.5.2. Oropharyngeal Cancer Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Oropharyngeal Cancer Total Market Size in Spain
15.6.2. Oropharyngeal Cancer Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Oropharyngeal Cancer Total Market Size in the United Kingdom
15.7.2. Oropharyngeal Cancer Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Oropharyngeal Cancer Total Market Size in Japan
15.8.3. Oropharyngeal Cancer Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Oropharyngeal Cancer
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
*The table of contents is not exhaustive; the final content may vary.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/